Fig. 5

The efficacy of laquinimod to suppress EAE partially depends on NK cells. a EAE severity of 2D2 T cell transferred Rag1^−/− mice continuously depleted of NK cells by αNK1.1 (PK136) antibody application and treated with 25 mg/kg laquinimod or vehicle. Data are representative of two independent experiments and are depicted as mean ± S.E.M. N = 6 mice/group; ***P < 0.001, two way ANOVA. b EAE severity of MOG_35–55 immunized Th/+ mice efficiently depleted of NK cells by αNK1.1 antibodies (PK136) and treated with laquinimod or vehicle for 28 days. Data are pooled from two independent experiments with and are depicted as mean ± S.E.M (n = 13 mice for vehicle-treated NK cell competent group, n = 14 mice for all other groups). *P < 0.05, between laquinimod-treated NK cell-competent or NK cell-deficient Th/+ mice, two way ANOVA. c Survival of EAE diseased Th/+ mice according to NK cell and treatment status. Data are pooled from two independent experiments. *P < 0.05, log-rank test